Decode the G‑BA
with MBM Future Health
♣ Ensure that patients receive the best possible treatment.
♣ Achieve a fair reimbursement for your medicine.
♣ Reach your full potential in the AMNOG procedure.
♣ Ultimately, rely on my long-standing experience at the G-BA. ♣
Identifying the best strategy for a global clinical development of innovative medicines is extremely challenging.
Uncertainty increases when evidence is scarce, as it is often the case in rare diseases and precision medicine. What is the best value proposition for future assessment and reimbursement? Which endpoints will – in the end – be considered patient-relevant? Is the launch in Germany a good option?
♣ Together with you, I identify the best scenario to ensure optimum results for your medicine. ♣
Launching a product is a critical task.
Procedures at the G-BA are complex. Decision-making authorities are difficult to understand. How to decrypt evidence-based decision making? How to make an informed decision on your individual case with your team?
♣ Get tailored advice on decision-making procedures at the G‑BA for your individual case. ♣
Your unique benefits
G-BA Expertise
You benefit from my long-standing experience as G-BA Officer.
Your personal Expert
You receive advice solely from me.
Operating worldwide
You want me in person!
Dr. Meriem Bouslouk-Marx
MEET
Dr. Meriem Bouslouk-Marx
♣ Extensive experience at the G-BA ♣ Individual advice for a wide range of therapeutic areas ♣ First-hand knowledge of evidence-based decision criteria for reimbursement ♣ Specialisation in Orphan Drugs including Cell and Gene Therapy Products ♣ Scientific Consultation ♣ Professional Network with Complementary Expertise ♣ Medical background including Tropical Medicine ♣ Public Health projects ♣ International Experience ♣ Multilingual (German, French, Arabic, English) ♣ Lecturer in Market Access ♣ Public Speaker ♣